Impact of occult HBV infection in HIV/HCV co-infected patients: HBV-DNA detection in liver speciments and in serum samples

Current HIV Research

Volumn 6, Issue 2, 2008, Pages 173-179

  Fabris, Paolo ^a   Biasin, Maria R ^b   Giordani, Maria T ^a   Berardo, Laura ^b   Menini, Vania ^b   Carlotto, Antonio ^c   Miotti, Maria G ^a   Manfrin, Vinicio ^a   Baldo, Vincenzo ^d   Nebbia, Gaia ^e   Infantolino, Domenico ^b  

^a SAN BORTOLO HOSPITAL   (Italy)

^b Castelfranco Veneto Hospital   (Italy)

^c SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic hepatitis; HBV DNA; HIV HCV co infection; Occult HBV

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIRETROVIRUS AGENT; EMTRICITABINE; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; VIRUS RNA; HEPATITIS C ANTIBODY;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYTICAL EQUIPMENT; BLOOD ANALYSIS; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DNA DETERMINATION; DNA EXTRACTION; FEMALE; GENE AMPLIFICATION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; QUANTITATIVE ASSAY; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SERODIAGNOSIS; STATISTICAL ANALYSIS; VIRUS LOAD; ARTICLE; BIOPSY; BLOOD; GENETICS; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; LIVER; MIDDLE AGED; PATHOLOGY; PREVALENCE; SERUM; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; BIOPSY; BLOOD; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HIV-1; HUMANS; LIVER; MALE; MIDDLE AGED; PREVALENCE; SERUM; VIRAL LOAD;

EID: 41249094464     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208783885029     Document Type: Review

References (39)

1. Cacciola I, Pollicino T, Squadrito G, et al. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999; 341: 22-26.
2. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002; 2: 479-486.
3. Torbenson M, Kannangai R, Astemborski J, et al. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004; 39: 51-57.
4. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002; 9: 243-257.
5. Fabris P, Brown D, Tositti G, et al. Occult hepatitis B virus infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004; 29: 160-166.
6. Minuk GY, Sun DF, Uhanova J, et al. Occult hepatitis B virus infection in a North American community-based population. J Hepatol 2005; 42: 480-485.
7. Chemin I, Jeantet D, Kay A, Trópo C. Role of silent hepatitis B virus in chronic hepatitis B surface antigen (-) liver disease. Antiviral Res 2001; 52: 117-123.
8. De Maria N, Colantoni A, Friedlander L, et al. The impact of previous HBV infection in patients with chronic hepatitis C. Am J Gastroenterol 2000; 95: 3529-3236.
9. Pollicino T, Squadrito G, Cerenzia G, et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology 2004; 126: 102-110.
10. Hui CK, Lau E, Wu H, et al. Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006; 35: 185-192.
11. Fukuda R, Ishimura. N, Niigaki M, et al. Serologically silent hepatitis B virus co-infection in patients with hepatitis C virus-associated chronic liver disease: clinical and virological significance. J Med Virol 1999; 58: 201-207.
12. Kazemi-Shirazi L, Petermann D, Muller C. Hepatitis B virus DNA in sera and liver tissue of HBsAg negative patients with chronic hepatitis C. J Hepatol 2000; 33: 785-790.
13. Georgiadou SP, Zachou K, Rigopoulou E, et al. Occult hepatitis B virus infection in Greek patients with chronic hepatitis C and in patients with diverse nonviral hepatic diseases. J Viral Hepat 2004; 11: 358-365.
14. Hui CK, Lau E, Monto A, Kim M, et al. Natural history of patients with recurrent chronic hepatitis C virus and occult hepatitis B coinfection after liver transplantation. Am J Transplant 2006; 6: 1600-1608.
15. Fabris P, Barnes E, Tositti G, et al. Therapy of chronic hepatitis C virus infection in HIV co-infected people. Curr Pharm Des 2004; 10: 2111-2122.
16. Nunez M, Rios P, Perez-Olmeda M, Soriano V. Lack of "occult" hepatitis B virus infection in HIV-infected patients. AIDS 2002; 16: 1099-1101.
17. Piroth L, Binquet C, Vergne M, et al. The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV-infected patients. J Hepatol 2002; 36: 681-686.
18. Santos EA, Yoshida CF, Rolla VC, et al. Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type-1. Eur J Clin Microbiol Infect Dis 2003; 22: 92-98.
19. Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869-875.
20. Wagner AA, Denis F, Weinbreck P, et al. Serological pattern "anti hepatitis B core alone" in HIV or hepatitis C virus-infected patients is not fully explained by hepatitis B surface antigen mutants. AIDS 2004; 18: 569-571.
21. Neau D, Winnock M, Jouvencel AC, et al. Groupe d'Epidemiologie Clinique du SIDA en Aquitaine. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine Cohort, 2002-2001. Clin Infect Dis 2005; 40: 750-753.
22. Hofer M, Joller-Jemelka HI, Grob PJ, Lüthy R, Opravil M. Frequent chronic HBV hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998; 17: 6-3.
23. Fabris P, Floreani A, Carlotto A, et al. Alcohol is an Important Cofactor for both Steatosis and Fibrosis in Northern Italian Patients with Chronic Hepatitis C. J Hepatol 2004; 41: 644-651.
24. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998; 27: 1736-1742.
25. Ghen Y, Sze J, He ML. HBV cccDNA in patients' sera as indicator for HBV reactivation. World J Gastroenterol 2004; 10: 82-85.
26. Conjeevaram HS, Lok AS. Occult hepatitis B virus infection: a hidden menace? Hepatology 2001; 34: 204-206.
27. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007; 46: 160-170.
28. Imberti L, Cariani E, Bettinardi A, et al. An immunoassay for specific amplified HCV sequences. J Virol Methods 1991; 34: 233-243.
29. Viazov S, Zibert A, Ramakrishnan K, et al. Typing of hepatitis C virus isolates by DNA enzyme immunoassay. J Virol Methods 1994; 48: 81-91.
30. Hui CK, Sun J, Au WY, et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005; 42: 813-819.
31. Hui CK, Sun J, Au WY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006; 31: 59-68.
32. Rodríguez-Torres M, Gonzalez-Garcia J, Bräau N, et al. Occult hepatitis B virus (HBV) infection in the settino of HCV/HIV coinfection: clinically relevant or a diagnotic problem? J Med Virol 2007; 79: 694-700.
33. Shire NJ, Rouster SD, Stanford SD, et al. The Prevalence and Significance of Occult Hepatitis B Virus in a Prospective Cohort of HIV-Infected Patients. J Acquit Immune Defic Syndr 2007; 44: 309-314.
34. Re VL 3rd, Frank I, Gross R, et al. Risk Factors, and Outcomes for Occult Hepatitis B Virus Infection Among HIV-Infected Patients. J Acquit Immune Defic Syndr 2007; 44: 315-320.
35. Tsui JI, French AL, Seaberg EC, et al. Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women. Clin Infect Dis 2007; 45: 736-740.
36. Rodríguez-Torres M, Rodríguez-Orengo JF, Ríos-Bedoya CF, et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 2007; 46: 613-619.
37. Rouphael NG, Talati NJ, Rimland D. Hepatitis B reverse seroconversion in HIV-positive patients: case series and review of the literature. AIDS 2007; 21: 771-774.
38. Schnepf N, Sellier P, Bendenoun M, et al. Reactivation of lamivudine-resistant occult hepatitis B in an HIV-infected patient undergoing cytotoxic chemotherapy. J Clin Virol 2007; 39: 48-50.
39. Tamori A, Nishiguchi S, Kubo S, et al. HBV DNA integration and HBV-transcript expression in non-B, non-C hepatocellular carcinoma in Japan. J Med Virol 2003; 71: 492-498.